98%
921
2 minutes
20
Aims: To investigate associations of glomerular hyperfiltration with other metabolic factors in a nationally representative dataset.
Methods: We analyzed cross-sectional data from 15,918 subjects with estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 and urine albumin creation ratio (ACR) <30 mg/g, who participated in the 5th and 6th Korea National Health and Nutrition Examination Surveys. Hyperfiltration was defined as eGFR (CKD-EPI equation) exceeding the age- and sex-specific 95th percentile for healthy control subjects.
Results: Prevalence of hyperfiltration was 5.2% and that among normal, prediabetic, and diabetic subjects was 4.9%, 5.6%, and 7.3%, respectively, after adjusting for age, sex, and body weight (p for trend = 0.008). In a multiple logistic regression analysis, hyperfiltration was associated with a body mass index ≥30 kg/m2 [odds ratio (OR) = 3.461, p<0.001], waist circumference 85 cm (men) or 80 cm (women) (OR = 1.425, p = 0.015), systolic blood pressure 120-129 mmHg (OR = 1.644, p = 0.022), fasting plasma glucose 140 mg/dL (OR = 1.695, p = 0.033) and t serum triglyceride level 500 mg/dL (OR = 2.988, p = 0.001), and was independently associated with the ACR (B = 0.053, p<0.001).
Conclusions: In a general Korean population, both hyperfiltration and ACR were associated with similar metabolic parameters, and hyperfiltration correlated independently with a high ACR. Longitudinal studies are needed to further explore risks of hyperfiltration and microalbuminuria.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283579 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0207843 | PLOS |
Clin Transplant
September 2025
Department of Nephrology, Atılım University Faculty of Medicine, Ankara, Turkey.
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have demonstrated renoprotective and cardioprotective benefits beyond their antiglycemic effects. Their potential utility in kidney transplant recipients (KTRs) for preserving graft function and reducing rejection risk is currently under active investigation. Preliminary studies indicate that SGLT-2i therapy stabilizes estimated glomerular filtration rate (eGFR), decreases glomerular hyperfiltration, and improves metabolic outcomes in KTRs.
View Article and Find Full Text PDFSurg Obes Relat Dis
August 2025
Department of Internal Medicine, Division of Nephrology and Hypertension, Iwate Medical University School of Medicine, Yahaba, Iwate, Japan.
Background: Patients with severe obesity have glomerular hyperfiltration even without the overt renal dysfunction, but improvements are reported with metabolic surgery (MS). However, the mechanism underlying these effects of MS has not been investigated.
Objective: The aim of the present study was to determine whether MS for patients with severe obesity alters retroperitoneal adipose tissue (RAT) and kidney volume (KV), and whether these alterations lead to improvements in renal function and hypertension (HTN).
Metabolites
August 2025
Grupo de Investigación en Enfermedades Cardiorrenales y Metabólicas, Departamento de Medicina y Cirugía, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, CEU Universities, C/Santiago Ramón y Cajal s/n, 46115 Valencia, Spain.
: Sodium-glucose cotransporter-2 inhibitors (SGLT2is), initially developed as antihyperglycemic agents, have emerged as multifunctional therapeutics with profound cardiorenal and metabolic benefits. Their unique insulin-independent mechanism, targeting renal glucose reabsorption, distinguishes them from conventional antidiabetic drugs. : SGLT2is induce glycosuria, reduce hyperglycemia, and promote weight loss through increased caloric excretion.
View Article and Find Full Text PDFFront Med (Lausanne)
August 2025
Department of Nephrology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, China.
Diabetic kidney disease (DKD) has emerged as the leading cause of chronic kidney disease (CKD) worldwide, surpassing primary glomerular disorders in prevalence. Despite recent therapeutic advances, current treatment strategies primarily alleviate symptoms rather than address the underlying pathogenic mechanisms, highlighting an urgent need for targeted, mechanism-based interventions. The pathogenesis of DKD involves a complex interplay of metabolic, hemodynamic, inflammatory, oxidative, and fibrotic pathways.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
August 2025
Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France.
Introduction: In X-linked Hypophosphatemia (XLH), phosphate and vitamin D analogs increase the risk of nephrocalcinosis and renal impairment. Kidney function assessment is challenging, as creatinine-based eGFR may overestimate GFR due to reduced muscle mass. Cystatin C may be alternatively used.
View Article and Find Full Text PDF